These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Restricted motility for vertical strabismus in Graves' ophthalmopathy. Cruz OA Ophthalmology; 2001 Feb; 108(2):242-3. PubMed ID: 11158789 [No Abstract] [Full Text] [Related]
6. Correction of restricted extraocular muscle motility in surgical management of strabismus in graves' ophthalmopathy. Nguyen VT; Park DJ; Levin L; Feldon SE Ophthalmology; 2002 Feb; 109(2):384-8. PubMed ID: 11825827 [TBL] [Abstract][Full Text] [Related]
7. Correlation Between Optical Coherence Tomography and Magnetic Resonance Imaging of Rectus Muscle Thickness Measurements in Graves' Ophthalmopathy. De-Pablo-Gómez-de-Liaño L; Fernández-Vigo JI; Merino-Menéndez S; Duque-Muñoz M; Gómez-de-Liaño R J Pediatr Ophthalmol Strabismus; 2019 Sep; 56(5):319-326. PubMed ID: 31545866 [TBL] [Abstract][Full Text] [Related]
8. The role of restricted motility in determining outcomes for vertical strabismus surgery in Graves' ophthalmology. Prendiville P; Chopra M; Gauderman WJ; Feldon SE Ophthalmology; 2000 Mar; 107(3):545-9. PubMed ID: 10711893 [TBL] [Abstract][Full Text] [Related]
9. Graves' ophthalmopathy: V. Aetiology of upper eyelid retraction in Graves' ophthalmopathy. Feldon SE; Levin L Br J Ophthalmol; 1990 Aug; 74(8):484-5. PubMed ID: 2390525 [TBL] [Abstract][Full Text] [Related]
11. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. Villadolid MC; Yokoyama N; Izumi M; Nishikawa T; Kimura H; Ashizawa K; Kiriyama T; Uetani M; Nagataki S J Clin Endocrinol Metab; 1995 Sep; 80(9):2830-3. PubMed ID: 7673432 [TBL] [Abstract][Full Text] [Related]
12. [Value of electrophysiology in ophthalmologic monitoring of patients with endocrine orbitopathy]. Weik R; Ruprecht KW Klin Monbl Augenheilkd; 1995 Jun; 206(6):446-50. PubMed ID: 7666646 [TBL] [Abstract][Full Text] [Related]
13. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908 [TBL] [Abstract][Full Text] [Related]
18. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy. Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139 [TBL] [Abstract][Full Text] [Related]
19. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210 [TBL] [Abstract][Full Text] [Related]
20. [Injection of methylprednisolone directly into the extraocular muscles of eyes with disturbed motility secondary to Graves' ophthalmopathy. Preliminary report]. Mikita A; Mariak Z; Myśliwiec J Endokrynol Pol; 2005; 56(2):168-73. PubMed ID: 16335685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]